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Constrictive bronchiolitis results in airways obstruction with progressive lung hyperinﬂation causing
dyspnea and eventual respiratory failure. There are many known causes including rheumatic diseases,
infections and toxic inhalations. We describe a 58-year-old man with no preexisting lung disease who
suffered rapid loss of lung function with hyperinﬂation over months in association with rapidly
progressive radiographic bronchiectasis. Airway cultures grew Mycobacterium kansasii, Pseudomonas
aeruginosa and Aspergillus fumigatus; lung biopsy showed constrictive bronchiolitis that was clinically
idiopathic. His respiratory symptoms and pulmonary function rapidly improved within a week of high-
dose corticosteroid therapy. We suggest that a diagnosis of constrictive bronchiolitis should be consid-
ered in patients with a combination of new rapidly progressive lung hyperinﬂation and worsening
bronchiectasis. We hypothesize that the bronchiolitis-associated bronchiectasis may occur from
a predisposition for secondary infections known to cause large airway wall damage. Identiﬁcation and
adequate treatment of these infections is critical if concurrent high-dose corticosteroid therapy is
attempted to alleviate the constrictive bronchiolitis.
 2011 Elsevier Ltd. All rights reserved.1. Case report
A 58 years old man presented to pulmonary clinic with a history
of worsening dyspnea and thoracic CT scan abnormalities. He was
in good health without any respiratory problems until 9 months
before this visit. At that time, he ﬁrst noticed dyspnea on exertion
followed by productive cough and wheezing several weeks after
exposure to a ﬂooded basement. One month later, he was admitted
to an outside hospital with progressively worsening dyspnea. He
was treated with antibiotics and bronchodilators but showed no
improvement. He was a lifelong non-smoker and had no history of
asthma, allergies or occupational exposures. Cardiac evaluation and
chest x-ray were unremarkable. A chest CT scan revealed no inﬁl-
trates with borderline changes of bronchiectasis best seen in the
lower lobes (Fig. 1). Five months before this clinic visit, his respi-
ratory symptoms persisted and sputum was positive for Pseudo-
monas aeruginosa and Haemophilus parainﬂuenzae. Three months
before presenting to pulmonary clinic he additionally developed
night sweats and weight loss. Pulmonary function tests (PFT)
revealed moderate obstruction with an FEV1 of 1.01 L (26% of: þ1 410 550 2612.
rved.predicted) and FVC of 2.7 L (52% of predicted). He was started on
40 mg/day of prednisone and noted symptomatic improvement.
Bronchoscopy was performed and bronchoalveolar lavage cultures
were positive forMycobacterium kansasii and Aspergillus fumigatus.
Repeat CT scan showed a ﬁne nodular inﬁltrate and new diffuse
bronchiectasis (Fig. 2). The prednisone was rapidly tapered with
return of productive cough and worsening dyspnea prompting
evaluation at Johns Hopkins.1.1. Physical examination and laboratory data
His vital signs were normal except for a heart rate of 125 beats/
min. His lungs revealed diminished breath sounds and bilateral
lower lung ﬁeld rhonchi; the remainder of the examination was
normal. The complete blood count was signiﬁcant for a hematocrit
of 30% and a leukocyte concentration of 11,000/mm3 with 10%
eosinophils; platelets were normal. His blood chemistries were
normal. Serum IgG and IgA levels were mildly increased; the IgE
level of 429 U/ml was at the upper end of the normal range. His
erythrocyte sedimentation rate, alpha-1 antitrypsin, and serum
precipitins for Aspergillus, Micropolyspora faeni, Thermophilia vul-
garis, Thermoactinomyces saccharii, and pigeon proteins were
normal or negative. Anti-nuclear antibodies, rheumatoid factor and
Fig. 1. A chest CT scan showing borderline changes of bronchiectasis best seen in the
lower lobes.
Fig. 3. Repeat CT scan of the chest (4 months after Fig. 2) at the same level as Figs. 1
and 2 showing further progression of bilateral bronchiectasis.
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positive for M. kansasii. Pulmonary function testing revealed
progressive severe obstruction with FEV1 of 0.80 L, FVC 1.99 L, TLC
6.91 L (101% predicted), FRC 5.18 L (130% predicted), RV 4.14 L (171%
predicted) and CO diffusing capacity that was 52% of predicted. He
was started on an 18 month course of isoniazid 300 mg/day,
rifampin 600 mg/day and ethambutol 15 mg/kg/day for the
M. kansasii infection. A repeat chest CT was obtained (Fig. 3) before
proceeding with thoracoscopic lung biopsy. His biopsy demon-
strated constrictive bronchiolitis; no peribronchiolar granulomas
were observed (Fig. 4). Following the biopsy, he was continued on
anti-mycobacterial therapy and pulsed with 1 g/day of methyl-
prednisolone for 3 days followed by 60 mg/day prednisone (with
a slow taper) as an attempted treatment for idiopathic constrictive
bronchiolitis. Thrice weekly empiric azithromycin as well as sulfa-
methoxazole/trimethoprim prophylaxis for Pneumocystis jirovecii
pneumonia were also initiated. He demonstrated a clinical
response within the ﬁrst week of corticosteroid treatment with less
dyspnea and resolution of productive cough. One month later, his
PFTs showed a marked improvement in obstruction, hyperinﬂation
and gas exchange (FEV1 1.06 L, FVC 2.61 L, TLC 94% predicted, FRC
102% predicted, RV 129% predicted and DLCO 70% predicted). He
completed 18 months of anti-mycobacterial therapy with tapering
of prednisone to 15 mg/day. PFTs showed no further improvement
but remained stable.Fig. 2. Repeat CT scan (4 months after Fig. 1) at the same level as Fig. 1 showing a ﬁne
nodular inﬁltrate and new bilateral bronchiectasis.2. Discussion
Constrictive bronchiolitis (or obliterative bronchiolitis) is
characterized by concentric peribronchiolar and submucosal
ﬁbrosis with luminal narrowing that is unresponsive to bron-
chodilators.1 Clinically, patients present with dyspnea, cough and
have severe progressive irreversible airways obstruction with
hyperinﬂation.2 The diffusing capacity for carbon monoxide can
be mildly to moderately reduced.3 It is important to differentiate
constrictive bronchiolitis from cryptogenic organizing pneumonia
(previously called bronchiolitis obliterans organizing pneumonia).
The latter is deﬁned pathologically as proliferating plugs of ﬁbrous
tissue within airway lumen surrounded by an organizing pneu-
monia whereas constrictive bronchiolitis involves only bronchi-
olar walls.4 Radiologic studies of constrictive bronchiolitis reveal
hyperinﬂation with or without evidence of ﬁne nodularity on
computed tomography.1 Expiratory CT images typically show
evidence of air trapping resulting in a pattern of mosaic attenu-
ation. A small percentage of patients with constrictive bron-
chiolitis, including those with idiopathic disease, present with
radiographic bronchiectasis.3,5
Lung biopsy is the gold standard test to diagnose constrictive
bronchiolitis.1e3 The most common causes are connective tissue
disorders (rheumatoid arthritis, eosinophilic fasciitis, systemic
lupus erythematosis), allograft-related (lung or bone marrowFig. 4. Thoracoscopic lung biopsy showing representative bronchiole with extensive
submucosal ﬁbrosis and near-obliteration of the lumen (hematoxylin-eosin, original
magniﬁcation 200).
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tional (NH3, NO2, butter ﬂavoring, ground zero dust), and miscella-
neous (hypersensitivity pneumonitis, carcinoid tumorlets,
paraneoplastic pemphigus, inﬂammatory bowel diseases). As in our
case, constrictive bronchiolitis can also be idiopathic. In some clin-
ical situations, such as rheumatoid arthritis, the rapid development
of respiratory failure with airways obstruction and clear hyperin-
ﬂated lungs is so likely to be secondary to constrictive bronchiolitis
that a lung biopsy is not necessary. In our patient, we elected to
pursue a lung biopsy because mycobacterial infection can rarely
cause a granulomatous bronchiolitis6,7 which could be treated
primarily with antibiotics instead of high-dose corticosteroids.
An unusual feature of constrictive bronchiolitis shown by our
patient was the development of rapidly progressive bronchiectasis
that occurred in association with the loss of lung function and air
trapping from the more distal bronchiolar obliteration. Other cau-
ses of adult-onset bronchiectasis including connective tissue
diseases, inﬂammatory bowel disease, common variable immuno-
deﬁciency or alpha-1 antitrypsin deﬁciency were excluded in our
patient by absent serologies, lack of compatible clinical features,
and normal serum levels of immunoglobulins and alpha-1 anti-
trypsin. Although the development of bronchiectasis has been
reported in association with idiopathic constrictive bronchiolitis,3
our report is the ﬁrst to document the time course of the large
airway dilatation.
The mechanism for bronchiectasis complicating constrictive
bronchiolitis is unknown. Based on our patient, one mechanism
may be related to the poor airway clearance from the diminished
expiratory airﬂow. This could, in turn, lead to secondary large
airway infections with organisms known to be associated with
bronchial damage such as atypical mycobacterium, P. aeruginosa or
A. fumigates. There is one previous report of idiopathic constrictive
bronchiolitis with an associated infection with M. kansasii.8 Thus,
we would suggest that constrictive bronchiolitis should be
considered in any patient with the rapid development of severe
obstructive lung disease in association with new-onset bronchiec-
tasis even if a known bronchiectasis-causing organism is identiﬁed
in the airways.
M. kansasii is generally the second common cause of non-
tuberculous mycobacterial lung disease in the United States.9 Tap
water is likely a major reservoir for M. kansasii. Patients present
with symptoms and radiological ﬁndings mimicking Mycobacte-
rium tuberculosis infection. Risk factors include pneumoconiosis,
COPD, previous nontuberculous mycobacterial infection, and an
immunocompromised state. Typical radiological ﬁndings include
cavitary inﬁltrates with an upper lobe predilection but rarely,
bronchiectasis can be the only abnormality. The presence of
compatible radiographic ﬁndings and a single positive broncho-
scopic culture or two positive sputums are sufﬁcient to make the
diagnosis and initiate treatment for M. kansasii.9
The signiﬁcance of the A. fumigateswas unclear butmay have just
been an airway colonizer.We considered the possibility that he could
have developed a concurrent allergic bronchopulmonary aspergil-
losis based on the presence of the proximal bronchiectasis and
eosinophilia. However, his IgEwas not elevated, serum precipitans to
A. fumigates were negative and A. fumigates is frequently cultured
from the sputum in patients with bronchiectasis and atypical myco-
bacterial infection, includingM.kansasii.10Moreover, eosinophiliahas
previously been reported in pulmonary mycobacterial infections.11,12His sputum Aspergillus and eosinophilia have not recurred follow-
ing anti-mycobacterial treatment although he has remained on
corticosteroids.
In general, there is no known effective treatment for idiopathic
constrictive bronchiolitis. There is some evidence to suggest that the
administration of amacrolide antibiotic, such as azithromycin, could
be of beneﬁt at least in the setting of transplant-associated obliter-
ativebronchiolitis.13 As in our patient, corticosteroid therapy is often
tried with a highly variable response. Although we were simulta-
neously treating hisM. kansasii infection, the rapid improvement in
pulmonary symptoms and lung function that occurred within
a week of initiating corticosteroids suggested that the constrictive
bronchiolitis was partially steroid responsive. We are currently
following him closely for evidence of further lung function deteri-
oration with consideration for lung transplantation if further
medical treatment proves to be unsuccessful.
Our report has several important clinical implications. First, the
development of new rapid bronchiectasis with airﬂow obstruction
and hyperinﬂation out of proportion to the bronchiectasis should
raise the possibility of constrictive bronchiolitis. Second, this
associated bronchiectasis could be a result of secondary infections
in the large airways because of the diminished expiratory airﬂow
from the bronchiolitis. Identifying and treating these secondary
infections is critical to halt the bronchiectasis and avoid further
infectious complications if an attempt is made to treat the
constrictive bronchiolitis with corticosteroid therapy.
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